Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome

Pediatr Blood Cancer. 2014 May;61(5):925-7. doi: 10.1002/pbc.24883. Epub 2013 Dec 2.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non-CR) (3-year EFS (95% confidence interval): 80.0% (20.4-96.9%) vs. 10.0% (0.6%-35.8%), P = 0.039).

Keywords: Down syndrome; acute myeloid leukemia; allogeneic stem cell transplantation; reduced intensity conditioning.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Down Syndrome / mortality
  • Down Syndrome / therapy*
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Infant
  • Infant, Newborn
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / therapy*
  • Prognosis
  • Remission Induction
  • Retrospective Studies
  • Survival Rate
  • Transplantation Conditioning*
  • Transplantation, Homologous